These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 1522359)

  • 1. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M; Berhe D
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiological characteristics of leprosy reactions: 15 years experience from north India.
    Kumar B; Dogra S; Kaur I
    Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):125-33. PubMed ID: 15301592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
    Kar HK; Sharma P
    Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for erythema nodosum leprosum.
    Manandhar R; LeMaster JW; Roche PW
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):436-44. PubMed ID: 1474282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
    Feuth M; Brandsma JW; Faber WR; Bhattarai B; Feuth T; Anderson AM
    Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
    Vijayakumaran P; Manimozhi N; Jesudasan K
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.
    Rea TH; Sieling PA
    Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):316-27. PubMed ID: 9934358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythema leprosum--after treatment of Lepromatous Leprosy.
    Eickelmann M; Steinhoff M; Metze D; Tomimori-Yamashita J; Sunderkötter C
    J Dtsch Dermatol Ges; 2010 Jun; 8(6):450-3. PubMed ID: 19922466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24 months WHO-MDT.
    Balagon M; Saunderson PR; Gelber RH
    Lepr Rev; 2011 Sep; 82(3):213-21. PubMed ID: 22125929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence and management of leprosy reaction in China in 2005.
    Shen J; Liu M; Zhou M; Wengzhong L
    Lepr Rev; 2009 Jun; 80(2):164-9. PubMed ID: 19743620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some unusual type 2 reactions in leprosy.
    Ramesh V; Pahwa M
    Int J Dermatol; 2010 Feb; 49(2):172-5. PubMed ID: 20465641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):161-72. PubMed ID: 1522358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexplained delayed nerve impairment in leprosy after treatment.
    Rosenberg NR; Faber WR; Vermeulen M
    Lepr Rev; 2003 Dec; 74(4):357-65. PubMed ID: 14750581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reaction cases treated at the Regional Leprosy Training and Research Institute, Aska, Orissa: a retrospective analysis.
    Santaram V; Porichha D
    Indian J Lepr; 2004; 76(4):310-20. PubMed ID: 16119141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current guidelines for leprosy treatment].
    Flageul B
    Bull Soc Pathol Exot; 2003 Jan; 96(5):357-61. PubMed ID: 15015839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiologic characteristics of leprosy reactions.
    Scollard DM; Smith T; Bhoopat L; Theetranont C; Rangdaeng S; Morens DM
    Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):559-67. PubMed ID: 7868954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.